Biotechnology company Seagen (NASDAQ:SGEN) has posted updated efficacy and safety data from a Phase 2 study (part C) evaluating the combination of Adcetris and nivolumab and chemotherapy agents doxorubicin and dacarbazine for the treatment of early-stage classical Hodgkin lymphoma (cHL).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The Adcetris combination is the only targeted therapy-inclusive treatment that has demonstrated a statistically significant overall survival benefit at a follow-up of six years while also lowering mortality risk by 41%.
In part C of the study, the treatment showed an overall response rate of 98% with a 93% complete response rate. Further, while there were no incidents of febrile neutropenia, follow-up remains ongoing and progression-free survival data is yet to be available.
Impressively, Adcetris has already bagged approval for seven indications in the U.S. and five indications in Europe.
Overall, the Street has a $228.92 consensus price target on Seagen alongside a Hold consensus rating. Shares of the company have already surged nearly 53.2% so far this year.
Read full Disclosure